(¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ : 2020-09-03±³À°ÀÏÀÚ : 2020-09-03
±³À°Àå¼Ò : ¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: µå·¡°ï¾¾Æ¼ ÇѶó·ë ¿Ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ & ¿ÀÇÁ¶óÀÎ º´Çà) Á¦13Â÷ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Çмú´ëȸ ¹× 2020 ±¹Á¦Çмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : °ÇØÁø
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°úÀÇ·áÁ¤Ã¥,
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:00~09:20 Latest findings from ASCO TAPUR study Richard L. SCHILSKY(ASCO Executive Vice President and Chief Medical Officer USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:20~09:40 Initiation of KOSMOS (Korean Precision Medicine Project) ±èÁöÇö(ºÐ´ç¼¿ï´ëº´¿ø)
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:40~09:45 Q&A -(-)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 09:45~10:00 CancerLINQ, ASCO Cory D. WIEGERT(ASCO EVP & Chief Executive Officer USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:00~10:15 Research application of CancerLINQ Robert S. MILLER(ASCO CancerLinQ USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:15~10:25 Integration of real-world data in oncology field in Korea->Exploration of real-world Korean oncology data (º¯°æ¿äû) Àå´ë¿µ(ÇѸ²´ëÇб³ÀÇ·á¿ø)
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:25~10:30 Q&A -(-)
ÈÞ½Ä 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:30~10:50 ()
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 10:50~11:30 Implementing a comprehensive translational oncology platform in precision medicine: challenges, opportunities, and new directions Gordon B. MILLS(Knight Cancer Institute USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 11:30~11:50 Turning hope into reality: We dream for a better tomorrow with Pembrolizumab (1L NSCLC) ÀÌ°æ¿ø(°æ»ó´ëÇб³º´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 11:50~12:10 Everything comes to those who challenge: What is the best regimen for 1L R/M HNSCC patients? ±è¹ü¼®(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 12:10~12:50 MSI- H (High microsatellite instability) : Predictive biomarkers in the era of precision medicine ±è½ÂÅÂ(»ï¼º¼¿ïº´¿ø)
ÈÞ½Ä 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 12:50~13:20 ()
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:20~13:30 Neoadjuvant and adjuvant immunotherapy trials in gastric cancer treatment Çѵ¿¼®(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:30~13:40 RECISTing for immunotherapy ÀÌÈ£¿¬(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:40~13:50 Anti-cancer immune therapy & medical care benefit: Practical issue and unmet need ±èÀÏȯ(ÇØ¿î´ë¹éº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 13:50~14:00 Optimal use of Immunoradiotherpy: Practical issue in radiation oncology ¼Û½Ã¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:00~14:10 Biomarker testing for cancer immunotherapy ½ÉÈ¿¼·(¼¼ºê¶õ½ºº´¿ø)
Åä·Ð 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:10~14:20 Panel Discussion -(-)
ÈÞ½Ä 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:20~14:40 ()
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 14:40~15:00 Overcoming resistance to EGFR inhibitor Helena A. Yu(Memorial Sloan Kettering Cancer Center USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:00~15:20 Overcoming resistance to ALK inhibitor ±èµ¿¿Ï(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:20~15:40 Biomarkers to immunotherapy ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 15:40~16:00 Emerging strategies for immunotherapy combination Solange PETERS(Lausanne University Hospital Switzerland)
ÈÞ½Ä 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:00~16:20 ()
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:20~16:40 RNA editing enzyme ADAR1 as an immuno-oncology target Jin Billy LI(Stanford University USA)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 16:40~17:00 A CRISPR-based screen for the functional assessment of BRCA1 variants ±è¿ë¼·(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:00~17:20 Genetic profiling of acanthotic seborrheic keratosis ÃÖ¹«¸²(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:20~17:40 Werner helicase is a synthetic-lethal target in mismatch repair deficient tumours Mathew J. GARNETT(Wellcome Sanger Institute UK)
±³À°½Ã°£ 09¿ù 03ÀÏ Room A (¿Â/¿ÀÇÁ¶óÀκ´Çà) 17:40~18:40 Functional genomics approaches to identify targetable dependencies in cancer cells Mathew J. GARNETT(Wellcome Sanger Institute UK)